HUTCHMED (China) Limited HCM
14.00 USD -0.41 (-2.81%)
As ofNov 18, 2026, 2:26 PM EST
13.77 Day range 14.04
9.77 52-week range 16.33
- YTD
- +4.99%
- 1 year
- -4.54%
News
globenewswire.com HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal…
seekingalpha.com HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcriptbenzinga.com Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent…
benzinga.com Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
benzinga.com HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned — ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…
benzinga.com HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…
